ARTICLE | Clinical News
Omadacycline: Ph III OPTIC data
April 7, 2017 7:18 PM UTC
Top-line data from 774 patients with CABP in the ITT population of the double-blind, international Phase III OPTIC trial showed that once-daily IV-to-oral omadacycline for 7-14 days met the FDA-define...
BCIQ Company Profiles
BCIQ Target Profiles